Skip to content

Effect of high frequency repetitive transcranial magnetic stimulation(rTMS) over brain on negative symptoms and cognitive functioning in schizophrenia

Effect of high frequency repetitive transcranial magnetic stimulation (rTMS) on negative symptoms and cognitive functioning in schizophrenia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/11/006397
Enrollment
30
Registered
2015-11-30
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- schizophrenia patients

Interventions

Intervention1: repetitive transcranial magnetic stimulation (rTMS): 20Hz, 5 sessions per week for the duration of 4 weeks. Control Intervention1: Sham TMS: Rotation of the coil at 90 degree angle to t

Sponsors

Nand Kumar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients meeting the ICD 10 clinical criteria for schizophrenia with an illness duration of at least 1 year. 2. Patients currently stabilized on same antipsychotics for a period of at least 4 weeks but have significant negative symptoms as assesed on PANSS negative symptom score being greater than equals to 15. 3. Patients or primary caregiver with capacity and willingness to give informed consent.

Exclusion criteria

Exclusion criteria: 1. Presence of co morbid Axis I disorders (using MINI) including substance abuse or dependence (other than caffeine or nicotine). 2. Any history of seizure except those therapeutically induced by ECT. 3. History of treatment with rTMS therapy. 4. Patients receiving or received any surgical procedures on brain. 5. Patients with implanted device or metal in the brain or head or cardiac pacemaker. 6. Facial tattoos with metallic or magnetic sensitive ink. 7. Known or suspected pregnancy 8. History suggestive of increased intracranial pressure; Space occupying brain lesion; History of cerebrovascular accident; Transient ischemic attack within two years; Dementia; Parkinson disease; Huntington chorea; or Multiple sclerosis as assessed clinically.

Design outcomes

Primary

MeasureTime frame
Improvement in negative symptoms and cognitive functionsTimepoint: 4 weeks

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactNand Kumar

AIIMS, New Delhi

nandkm2001@gmail.com9899943146

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026